Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2020 18:06 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2020...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2020 18:20 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020...
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
February 27, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
February 26, 2020 16:05 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020
February 19, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2020 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2020...
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
January 13, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it has appointed John C....
Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2019 18:06 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2019,...
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
December 23, 2019 01:00 ET
|
Sarepta Therapeutics, Inc.
– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States – – At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in...